Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled
study. Approximately 72 patients will be randomized 3:1 to treatment or placebo, with
approximately 54 patients allocated to receive the active investigational product and
approximately 18 patients allocated to receive placebo.
- Study Update-
Amendment 3 - In this amendment, an additional 80 patients (approximately) will be randomized
1:1 to treatment or placebo (double-blind) with approximately 40 subjects allocated to each
group.